4.6 Article

Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells

Journal

ALLERGY
Volume 70, Issue 8, Pages 910-920

Publisher

WILEY
DOI: 10.1111/all.12627

Keywords

asthma; innate immunity; interferon; Th2 inflammation; virus

Funding

  1. Chiesi
  2. AstraZeneca
  3. Boehringer Ingelheim
  4. Novartis
  5. Menarini
  6. Mundipharma
  7. Almirall
  8. Zambon
  9. Centocor
  10. Sanofi Pasteur
  11. GSK
  12. Grunenthal
  13. Synairgen
  14. AstraZeneca Italy
  15. GlaxoSmithKline
  16. Merck Sharp and Dohme
  17. Pfizer
  18. Takeda
  19. Asthma UK [MRC-Asthma UK Centre, RF07/04, CH11SJ] Funding Source: researchfish
  20. Medical Research Council [G1000758B, G1000758] Funding Source: researchfish

Ask authors/readers for more resources

BackgroundAsthma and other Th2 inflammatory conditions have been associated with increased susceptibility to viral infections. The mechanisms by which Th2 cytokines can influence immune responses to infections are largely unknown. MethodsWe measured the effects of Th2 cytokines (IL-4 and IL-13) on bronchial epithelial cell innate immune antiviral responses by assessing interferon (IFN- and IFN-1) induction following rhinovirus (RV)-16 infection. We also investigated the modulatory effects of Th2 cytokines on Toll-like receptor 3 (TLR3), interferon-responsive factor 3 (IRF3) and nuclear factor (NF)-kB, that is key molecules and transcription factors involved in the rhinovirus-induced interferon production and inflammatory cascade. Pharmacological and redox modulation of these pathways was also assessed. ResultsTh2 cytokines impaired RV-16-induced interferon production, increased rhinovirus replication and impaired TLR3 expression in bronchial epithelial cells. These results were replicated invivo: we found increased IL-4 mRNA levels in nasal epithelial cells from nasal brushing of atopic rhinitis patients and a parallel reduction in TLR3 expression and increased RV-16 replication compared to nonatopic subjects. Mechanistically, Th2 cytokines impaired RV-16-induced activation of IRF3, but had no effects on RV-16-induced NF-kB activation in bronchial epithelial cell cultures. N-acetylcysteine and phosphoinositide 3-kinase (PI3K) inhibitor restored the inhibitory effects of Th2 cytokines over RV-16-induced activation of IRF3. ConclusionsIL-4 and IL-13, through inhibition of TLR3 expression and signalling (IRF3), impair immune response to RV-16 infection. These data suggest that Th2 conditions increase susceptibility to infections and identify pharmacological approaches with potential to restore impaired immune response in these conditions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available